Clinical Resources

We have the chance to eliminate hepatitis C from Australia.

Australia is leading the world in reaching the goal of eliminating hepatitis C as a public health threat by 2030 because we have unrestricted access to DAAs and specialists, general practitioners and nurse practitioners can all prescribe hepatitis C treatment.

From March 2016 to December 2018, an estimated 70,260 people have been treated with DAAs. To reach our target we need to treat over 80% of people living with hepatitis C virus (HCV), reduce HCV-related deaths by 65% and reduce new HCV infections by 80%.

To make this happen, we need more general practitioners (GPs) and authorised nurse practitioners to treat hepatitis C and more primary care practices to prioritise hepatitis C within their busy clinics.

Some parts of Australia are leading the way in treating hepatitis C, and we can learn from them to improve access to treatments across Australia. Working in partnership is the only way we will achieve our goal of eliminating hepatitis C from Australia.

Resources

The project involves the GPLN working with GPs/NPs and other clinical and practice staff to increase their skills, knowledge and confidence in prescribing hepatitis C treatments.

The aim is to increase the number of people in Western Australia (WA) cured, and provide a sustainable workforce competent, confident and capable of prescribing hepatitis C treatments, and ultimately augment progress in the goal of elimination of hepatitis C from the community.

The next decade will be a crucial period in the public health response to hepatitis C. The rapid development and availability of direct-acting antiviral (DAA) therapy for hepatitis C has brought the potential of considerable momentum to therapeutic reform.  However, the number of people in Australia who are accessing hepatitis C treatments continues to decline. According to the Kirby Institute’s Monitoring hepatitis C treatment uptake in Australia (Issue 9), (The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia, July 2018), the monthly uptake of the therapies first listed on the Pharmaceutical Benefits Scheme in March 2016 has more than halved since peaking around this time.  Even more concerning, Western Australia appears to be trailing even further behind the rest of the country concerning people accessing the hepatitis C treatments.

Historically, General Practitioners (GPs) / Nurse Practitioners (NPs) referred patients with a positive hepatitis C serology for specialist treatment, and as such they were inexperienced in the full screening and management of a patient with hepatitis C.

To address this issue, HepatitisWA successfully applied for funding from the WA Department of Health (DoH) Sexual Health and Blood Borne Virus Program (SHBBVP) to implement a project aimed at supporting GPs/NPs to manage their patients rather than referring them to specialist services.

How Does the Project Work?

The DoH collates all positive hepatitis C notifications and associated GP/NP/ primary care practices from which the results have come.

The relevant GPs/ GP Practices are then notified of the results and at this time they are informed they will receive contact from HepatitisWA’s GP Liaison Nurse (GPLN) who is available to assist them with information, education and support around prescribing hepatitis C treatments, including pathways for referral.

At this time GPs/GP practices are given ten (10) days to opt out from receiving contact.